TherapeuticsMD, Inc.
TXMD
$2.21
-$0.03-1.34%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 20.03% | -18.92% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 20.03% | -18.92% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 20.03% | -18.92% | |||
| SG&A Expenses | 26.08% | -52.63% | |||
| Depreciation & Amortization | 1.06% | -3.09% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.55% | -50.05% | |||
| Operating Income | -35.92% | 78.74% | |||
| Income Before Tax | 59.22% | 117.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 59.22% | 116.83% | |||
| Earnings from Discontinued Operations | -12.50% | -14.29% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 63.16% | 115.35% | |||
| EBIT | -35.92% | 78.74% | |||
| EBITDA | -65.18% | 87.16% | |||
| EPS Basic | 63.41% | 115.33% | |||
| Normalized Basic EPS | 71.43% | 119.79% | |||
| EPS Diluted | 12.20% | 114.39% | |||
| Normalized Diluted EPS | 72.73% | 119.43% | |||
| Average Basic Shares Outstanding | 0.00% | -0.01% | |||
| Average Diluted Shares Outstanding | 0.03% | 0.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||